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S3 solution of NaHCO3 and extracted with CH2Cl2. The combined organic phases were washed with brine, dried over anhydrous Na2SO4 and concentrated under vacuum.
Purification by silica gel (hexane-ethyl acetate 9:1 and 0.5% TEA) gave compound 23 (4.1 g, 80% over two steps). NMR analysis demonstrated a diasteromeric ratio E/Z >95%. The E configuration at the exocyclic double bond was established by dipolar coupling H3-26 ( 1.67)/H-5 ( 2.62) in Noesy spectrum (400 MHz, mixing time 400 ms). 174.6, 170.7, 143.1, 130.2, 72.5, 54.5, 51.4, 50.7, 48.6, 45.2, 43.5, 39.1, 38.9, 35.1, 34.9, 34.1, 33.4, 31.0, 30.9, 28.4, 25.9 (2C), 22.8, 21.4, 21.2, 18.4, 12.7, 12.2 
. HR ESIMS m/z

[M+H]
+ , C29H45O5 requires 473.3267.
Methyl 3-acetoxy-6-ethyl-7-keto-5-cholan-24-oate (24).
A solution of 23 (4.0 g, 8.5 mmol) in THF dry/MeOH dry (100 mL, 1:1 v/v) was hydrogenated in presence of Pd(OH)2 20% wt on activated carbon (100 mg) degussa type. The mixture was transferred to a standard PARR apparatus and flushed with nitrogen and then with hydrogen several times. The apparatus was shacked under 50 psi of H2.
The reaction was stirred at room temperature for 8 h. The catalyst was filtered through Celite, and the recovered filtrate was concentrated under vacuum to give 24 (4.0 g, quantitative yield). The  configuration of ethyl group at C-6 was determined by dipolar couplings H3-26 ( 0.83)/ H3-19 ( .7, 174.3, 170.2, 72.6, 61.7, 54.8, 51.3, 49.0, 48.5, 45.3, 42.7, 42.3 (2C), 38.6, S4 35.4, 35.1, 35.0, 31.0, 30.8, 28.0 (2C), 26.4, 25.7, 24.7, 21.3, 21.1, 18.2, 12.9, 11.9 with MeONa in methanol to obtain deacetylation at C-3 and inversion at C-6. Tosylation, in the same operative condition previously described, 1 furnished 620 mg of 25 (quantitative yield over two steps)
that was subjected to the next step without further purification.
Lithium bromide (148 mg, 1.7 mmol) and lithium carbonate (125 mg, 1.7 mmol) were added to a solution of 6-ethyl-3-tosyloxy-7-keto-5-cholan-24-oate (500 mg, 0.85 mmol) in dry DMF (30 mL), and the mixture was refluxed for 2 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution (20 mL) and extracted with CH2Cl2 (3 × 50 mL). The combined organic layer was washed successively with water, saturated NaHCO3 solution and water, and then dried over anhydrous MgSO4 and evaporated to dryness to give 400 mg of oleos residue (quantitative yield), that was subjected to next step without any purification.
Hydrogenation on Pd(OH)2 in the same operative condition previously described furnished 312 mg of 26 (88% over two steps).
6-ethyl-7-hydroxy-5-cholan-24-ol (7) and 6-ethyl-7-hydroxy-5-cholan-24-ol (8). Dry methanol (70 µL, 1.7 mmol) and LiBH4 (850 L, 2 M in THF, 1.7 mmol) were added to a solution of the compound 26 (100 mg, 0.24 mmol) in dry THF (5 mL) at 0 °C under argon and the resulting mixture was stirred for 5 h at 0 °C. The mixture was quenched by addition of NaOH (1 M, 480 L) and then allowed to warm to room temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 ×15 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated to give a mixture of alcohols 7 and 8. HPLC purification on a Nucleodur 100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (92:8) as eluent (flow rate 3 mL/min), gave 64 mg of 6-ethyl-7-hydroxy-5-cholan-24-ol 7 (69%, tR= 31 min) and a small amount of 6-ethyl-7-hydroxy-5-cholan-24-ol 8 (8 mg, tR= 24.8 min). 71.6, 63.6, 57.6, 51.8, 48.7, 43.7, 43.3, 41.5, 41.1, 39.3, 37.5, 37.0, 34.6, 33.2, 30.3, 29.4, 28.8, 25.1, 24.6 (2C), 23.5, 22.5, 22.0, 19 57.9, 56.8, 46.3, 45.3, 45.0, 44.7, 41.7, 41.1, 38.8, 37.0, 36.3, 33.3, 30.3, 28.1, 27.9 (2C) 6-ethyl-7-hydroxy-5-cholan-24-yl 24-sodium sulfate (9). Sulfation on C-24 on a small aliquot of diol 7 (20 mg, 0.05 mmol) was performed in the same operative conditions previously described. In same embodiments LiBH4 treatment after alkaline hydrolysis produced small amounts (about 10%) of 6-ethyl-7-hydroxy-5-cholan-24-oic acid (11) that was isolated by HPLC purification on a Nucleodur 100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min, tR= 16 min). 71.6, 57.4, 51.7, 48.7, 43.8, 43.3, 41.5, 41.1, 39.3, 37.4, 36.8, 34.6, 32.5 (2C) 
6-ethyl-7-hydroxy-5-cholan-24-ol (7
6-ethyl-7-hydroxy-5-cholan-24-oic acid (10
6-ethyl-7-hydroxy-5-cholan-24-oic acid (11
6-ethyl-7-hydroxy-5-cholan-24-oyl taurine sodium sulfate (12).
An aliquot of 10 (10 mg, 0.024 mmol) in DMF dry (5 mL) was treated with DMT-MM (20.5 mg, 0.07 mmol) and triethylamine (83L, 0.6 mmol) and the mixture was stirred at room temperature for 10 min. Then to the mixture was added taurine (18 mg, 0.14 mmol). After 3 h, the reaction mixture was concentrated under vacuo and dissolved in water (5 mL). Purification on C18 silica gel column and then HPLC on a Nucleodur 100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (83:17) as eluent (flow rate 3 mL/min), gave 4.5 mg of 6-ethyl-7-hydroxy-5-cholan-24-oyl taurine sodium sulfate (12) (tR= 10 min). 
6-ethyl-7-hydroxy-5-cholan-24-ol (13) and 6-ethyl-7-hydroxy-5-cholan-24-ol (14).
To a methanol solution of 28 (350 mg, 0.84 mmol), a large excess of NaBH4 was added at 0 °C. The mixture was left at room temperature for 2 h and then water and MeOH were added dropwise during a period of 15 min at 0 °C with effervescence being observed. After evaporation of the solvents, the residue was diluted with water and extracted with ethyl acetate (3x50 mL). The combined extract was washed with brine, dried with Na2SO4, and evaporated to give 1.3 g of a crude residue that was subjected to the next step without further purification. The crude residue was treated with LiBH4 (2M in THF) in the same operative condition described for the synthesis of compounds 7 and 8. HPLC purification on a Nucleodur 100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (92:8) as eluent (flow rate 3 mL/min), furnished 180 mg of 6-ethyl-7-hydroxy-5-cholan-24-ol (13, 54%, tR= 25 min) and 75.4 mg of 6-ethyl-7-hydroxy-5-cholan-24-ol (14, 23%, tR= 13 min). 63.8, 57.6, 56.5, 44.2, 43.7, 42.8, 41.0, 40.9, 40.8, 38.2 (2C), 36.9, 34.4, 32.8, 29.7, 28.9, 27.0, 26.1, 24.7, 22 
6-ethyl-7-hydroxy-5-cholan-24-ol (13
Methyl 6-ethyl-3-hydroxy-7-keto-5-cholan-24-oate (29).
A solution of 27 (900 mg, 1.5 mmol) and CH3COOK (147 mg, 1.53 mmol) dissolved in water (2 mL) and N,N'-dimethylformamide (DMF, 10 mL) was refluxed for 2 h. The solution was cooled at room temperature and then ethyl acetate and water were added. The separated aqueous phase was extracted with ethyl acetate (3 ×30 mL). The combined organic phases were washed with water, dried (Na2SO4) and evaporated to dryness to give 1.0 g of mixture. Purification by silica gel (hexane-ethyl acetate 7:3 and 0.5% TEA) gave 500 mg of intermediate as oily oil. C-6 inversion in the same operative condition as described for the synthesis of compound 25, furnished compound 29 (500 mg, 74% over two steps 
6-ethyl-3,7-dihydroxy-5-cholan-24-ol (15) and 6-ethyl-3,7-dihydroxy-5-cholan-24-ol (16).
Intermediate 29 (500 mg, 1.16 mmol) was treated with LiBH4 as previously described. HPLC S9 purification on a Nucleodur 100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 250 mg of compound 15 as a white solid (53%, tR= 12.6 min) and a small amount of compound 16 (23 mg, 5%, tr=8.2 min). 67.4, 63.6, 57.6, 51.7, 43.7, 42.8, 41.5, 41.2, 41.1, 37.1 (2C), 33.8, 33.2, 31.3 (2C), 30.3, 29.4, 28.3, 24.6, 24.2, 23.3, 22.3, 19.2, 12.7, 12 63.6, 57.8, 56.8, 45.0, 44.8, 44.5, 41.7, 40.3, 39.1, 37.0, 35.9, 33.0, 31.2, 30.2, 29.8, 28.4, 28.0, 27.9, 24.8, 22.9, 21.8, 19.3, 12.8, 11.6 
6-ethyl-3,7-dihydroxy-5-cholan-24-ol (15
6-ethyl-3,7-dihydroxy-5-cholan-24-ol (16
6-ethyl-3,7-dihydroxy-5-cholan-24-oic acid (17) and 6-ethyl-3,7-dihydroxy-5-cholan-24-oic acid (18).
Compounds 17 and 18 (215 mg, 74% over two steps) was synthesized, starting from compound 29 (320 mg, 0.74 mmol), by an analogous procedure to that detailed above for compounds 10 and 11.
HPLC purification on a Nucleodur100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 208 mg of 17 as a white solid (65%, tR= 11 min). In same embodiments LiBH4 treatment after alkaline hydrolysis produced small amounts (about 10%) of 18 that was isolated by HPLC purification on a Nucleodur 100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min, 28 mg of 18, 9%, tR= 8 min). 178.3, 71.3, 67.5, 57.4, 51.7, 43.8, 42.8, 41.5, 41.2, 41.0, 37.0, 36.7, 33.8, 32.4, 32.0, 31.1 (2C), 29.3, 28.3, 24.6, 24.2, 23.3, 22.2, 18.8, 12.3, 12 
S10
6-ethyl-3,7-dihydroxy-5-cholan-24-oic acid (17
6-ethyl-3,7-dihydroxy-5-cholan-24-oyl taurine sodium sulfate (19).
Compound 19 was synthesized, starting from compound 17 (10 mg, 0.023 mmol), by an analogous procedure to that detailed above for compound 12. 
6-ethyl-3,7-dihydroxy-5-cholan-24-ol (20) and 6-ethyl-3,7-dihydroxy-5-cholan-24-ol (21).
Compound 27 was treated with CH3COOK as previously described for compound 29.
NaBH4/LiBH4 reduction on the corresponding 7-keto intermediate (100 mg, 0.23 mmol) in the same operative conditions described for the synthesis of compounds 13 and 14 afforded a mixture whose HPLC purification on a Nucleodur 100-5 C18 (5 m; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12)
as eluent (flow rate 3 mL/min), gave 48.3 mg of 20 (52 % over two steps, tR= 11 min) and 20.7 mg of 21 (22 % over two steps, tR= 13 min). .8, 67.4, 63.4, 57.2, 51.3, 51.2, 43.2, 41.6, 40.5, 37.3, 37.1 (2C), 36.9, 34.0, 33.3, 32.1, 30.3, 29.3, 28.9, 28.6, 26.3, 24.9, 22.0, 19.3, 13.8, 12 
6-ethyl-3,7-dihydroxy-5-cholan-24-ol (20
6-ethyl-chenodeoxycholic acid (6).
Compound 24 (500 mg, 1.05 mmol) was hydrolyzed with NaOH (208 mg, 5.2 mmol) in a solution of MeOH:H2O 1:1 v/v (10 mL), as previously described.
The mixture was stirred for 5 h at reflux. The resulting solution was then acidified with HCl 6N and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to give the carboxylic acid intermediate 30. This compound was subjected to the LiBH4 reduction of the C7-carbonyl group.
Purification gave 305 mg of 6-ECDCA (6) as a white solid (69% over two steps).
Bile acids determination
Sample preparation. The stock solutions of the individual tauro-conjugated and un-conjugated bile acids were prepared separately in methanol at a concentration of 1 mg/mL. All stock solutions were stored at −20 • C. Calibration standards were prepared by combining appropriate volumes of each bile acid stock solution and methanol. The calibration range was from 10 nM to 100 μM of each bile acid in the final solution. Mice serum sample aliquots of 100 μL were deproteinized with 1 mL of cold acetonitrile with 5% of NH4OH vortexing for 1 min. After centrifugation at 16000 g for 10 min, the clear supernatant was transferred to a new vial, snap frozen and lyophilized. The sample was then re-dissolved in methanol-water (2:1, v/v) for tauro-conjugated bile acids determination and in methanol-ammonium acetate 10 mM with 0.005% formic acid (3:2, v/v) for un-conjugated bile acids determination. A bile acids extraction yield of 95% has been estimated.
Liquid chromatography and mass spectrometry. For LC-MS/MS analysis, chromatographic
separation was carried out on the HPLC-MS system LTQ XL ThermoScientific equipped with Accelera 600 Pump and Accelera AutoSampler system. The mixture was separated on a Jupiter 5μC18 column from Phenomenex (150 x 2.00 mm). Tauro-conjugated bile acids were separated at a flow rate of 200 μl/min using a methanol-aqueous ammonium acetate (NH4OAc) gradient. Mobile phase A was 5% methanol in water containing 2 mM ammonium acetate at pH 7, mobile phase B was methanol, containing ammonium acetate at 2 mM. The gradient started at 30 % B and increased to 100% B in 20 min, kept at 100% B for 5 min then decreased to 30% B in 1 min and kept at 30% B for 10 min. ESI was performed in negative ion mode, the ion source temperature was set at 280 • C.
The tune page parameters were automatically optimized injecting taurocholic acid at 1 μM as standard. The MS/MS detection was operated in MRM mode using a collision energy of 20 (arbitrary units), the observed transitions were: tauromuricholic acid (t-MCA) at 13. Mice serum sample aliquots of 50 μL were deproteinized with 500 μL of cold acetonitrile with 5% of NH4OH vortexing for 60 min. After centrifugation at 16000 g for 10 min, the clear supernatant was transferred to a new vial, snap frozen and lyophilized. The sample was then re-dissolved in 50 μL of MeOH. Later on, 10 μL of glacial acetic acid and 10 mg of Girard T reagent (diluted in 40 μL of water) were added and kept in the dark at r.t. overnight (final volume of 100 μL).
Liquid chromatography and mass spectrometry analysis. For LC-MS/MS analysis, chromatographic separation was carried out on the HPLC-MS system LTQ XL ThermoScientific equipped with Accelera 600 Pump and Accelera AutoSampler system. The mixture was separated on a Jupiter C18 column from Phenomenex (150 x 2.00 mm) and the column flow rate was set at 150 µL/min. Samples were separated using a acetonitrile-metanol-aqueous gradient. Mobile phase A was water/MeOH/ACN at 50/33.3/16.7% in 0.1% TFA, mobile phase B was MeOH/ACN at 66.6/33.4% in 0.1% TFA. The gradient started at 35% B and increased to 95% B in 15 min, kept at 95% B for 10 min then decreased to 35% B in 1 min and kept at 35% B for 10 min. ESI was performed in positive ion mode, the ion source temperature was set at 280 • C. The MS/MS detection was operated using a collision energy of 40 (arbitrary units). 7-hydroxy-4-cholesten-3-one modified by GT reagent gave Figure S1 . Concentration-response curve of 6-ECDCA (6) on FXR in a luciferase reporter assay using HepG2 cells transfected with FXR. Twenty-four hour post transfection cells were stimulated with increasing concentrations of 6: range from 100 nM to 10 µM. Results are expressed as mean ± standard error. EC 50 : 500nM
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